Salute e Benessere

AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer…

AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026LONDON and PHOENIX, Ariz., March18, 2025(GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer, announces the acquisition of the license for the proprietary microRNA Signature Classifier (MSC) test. The inventors of the proprietary lung cancer screening test will continue to...
Nasdaq GlobeNewswire
18/03/2025

Alvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application…

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy's”) and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, developed by Alvotech, a proposed biosimilar of...
Nasdaq GlobeNewswire
18/03/2025

Kimia Therapeutics Appoints Imran S. Haque, Ph.D. as Chief Technology Officer

Dr. Haque brings to Kimia nearly 20 years of experience at the interface among chemistry, biology, and machine learning. At Recursion, he built and led the data science and machine learning team that spanned platform development through therapeutic discovery to transform how drugs can be discovered using high-dimensional biological data and AI, and was technical lead for Recursion's M&A and partnering efforts (including partnerships with Roche/Genentech, Tempus, and Helix; and its...
Nasdaq GlobeNewswire
18/03/2025

Nuralogix Announces Its Next-Generation Anura® MagicMirror™: Advanced Health…

Revolutionizing Health Monitoring with AI-Powered Insights Revolutionizing Health Monitoring with AI-Powered Insights The MagicMirror is the first smart mirror that uses Nuralogix proprietary Transdermal Optical Imaging (TOI™) technology to analyze facial blood flow and extract comprehensive health insights in just 30 seconds. Integrated with the company's cloud-based DeepAffex™ platform, the mirror provides over 100 health parameters, including: With the addition of 4G connectivity,...
PR Newswire
18/03/2025

EAACI Congress 2025 - Breaking Boundaries in Allergy, Asthma, and Clinical…

Scientific Excellence & Global Collaboration Bringing together leading experts from across the world, EAACI Congress 2025 is the premier event for networking and collaboration in allergy and immunology. Delegates can expect cutting-edge research presentations, interactive sessions, and invaluable opportunities to connect with peers shaping the future of the field.Visit the scientific programme to learn more. Premier Venue & Registration Details The congress will be hosted...
Nasdaq GlobeNewswire
18/03/2025

EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a…

EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)EBX-102-02 demonstrated clinically meaningful superiority over placebo in key efficacy assessments in patients with moderate to severe IBS-CEBX-102-02 was demonstrated to be well-tolerated Glasgow, Scotland – 18 March 2025.EnteroBiotix Limited ('EnteroBiotix'), a clinical-stage biopharmaceutical company focussed on developing...
Nasdaq GlobeNewswire
18/03/2025

Oncorena receives FDA approval to initiate studies in the US

The study is currently being conducted at Karolinska University Hospital in Stockholm, Sweden. The study is currently being conducted at Karolinska University Hospital inStockholm, Sweden. Börje Haraldsson, CEO & co-founder of Oncorena comments: "This approval brings us closer to being able to evaluate the potential for this novel treatment in patients in desperate need for new and better options. We are excited to start the first US site, MD Andersson inHouston, Texas, where...
PR Newswire
18/03/2025

Medit Launches a New All-on-X Solution, Medit SmartX

Key Features of Medit SmartX include: Key Features of Medit SmartX include: Medit revolutionized the market in 2018 with its first intraoral scanner, offering high precision and user-friendly options at a significantly lower cost than competitors. Following this success, Medit introduced its best-sellingi 700 in 2021,i 700 Wireless, andi 600 in 2022, andi 900 in 2024, providing a complete range of scanners for all types of dental practices. Medit is expanding its influence...
PR Newswire
18/03/2025

PrimeBiome Faces Unexpected Stock Shortages in Q1 as Consumer Demand Outpaces…

In the first quarter of 2025, the rapid growth in consumer interest for PrimeBiome gummies has led to supply constraints across multiple sales channels. Industry analysts note that heightened awareness around gut-skin health supplements has contributed to the surge in demand, with buyers actively searching for PrimeBiome reviews and recommendations. In the first quarter of 2025, the rapid growth in consumer interest for PrimeBiome gummies has led to supply constraints across multiple sales…
PR Newswire
18/03/2025

Tecan publishes agenda for the Annual General Meeting 2025

Tecan publishes agenda for the Annual General Meeting 2025Board of Directors will propose the re-election of seven current membersKaren Huebscher will not be standing for re-election Myra Eskes, Christa Kreuzburg and Daniel R. Marshak proposed for re-election to the Compensation CommitteeReport of non-financial matters submitted for approval for the first time with an audit certificateProposal for a stable dividend of CHF 3.00 per share, reflectingsolid cash flows and...
Nasdaq GlobeNewswire
18/03/2025

Press release: Sequana Medical announces 2024 Full Year Results and 2025 Outlook

Sequana Medical announces 2024 Full Year Results and 2025 Outlookalfapump® – US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial launch planned for mid Q3 2025DSR® – Publication of RED DESERT and SAHARA data in peer-reviewed “European Journal of Heart Failure” highlights DSR as potential treatment for Cardiorenal Syndrome; Positive data from non-randomized cohort in US MOJAVE study, DSMB approval to start...
Nasdaq GlobeNewswire
18/03/2025

Press release: Sequana Medical Obtains Convertible Financing of EUR 4.0 Million…

Sequana Medical Obtains Convertible Financing of EUR 4.0 Million from Major Shareholders and Committed Share Subscription Facility of up to EUR 60 Million from GEM Continued support from major shareholders – new EUR 4.0 million convertible loan financing from Partners in Equity and EQTCommitted share subscription facility of up to EUR 60 million from GEM New financing is combined with a restructuring of the Company's existing loansCash runway extended to the end of 2025...
Nasdaq GlobeNewswire
18/03/2025

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issuance of bi-weekly default status reports in the form of news releases, for so long as the Company remains in default with its Required Filings; (ii) the Company does not have any information at this time…
PR Newswire
18/03/2025

Total Investment of Approx. USD 11.4 Million in Schistosomiasis Diagnostics and…

The project will advance the development of a rapid diagnostic test (RDT) for Schistosoma mansoni, leveraging previous research findings and evaluating the diagnostic performance of the candidate RDT in endemic regions of Africa. In addition, the project team will develop a new serological RDT for Schistosoma haematobium. These tests are expected to be used as a low-cost, easy-to-use point-of-care (POC) diagnostic to support decision-making for Interruption of Transmission/Stopping Mass Drug…
PR Newswire
18/03/2025

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing…

The marketing authorization is granted to Telix's partner R2PHARMA, Brazil's leading cold kit manufacturer, nuclear pharmacy and cyclotron network, and a subsidiary of GSH Corp Participações S.A. (Grupo GSH). Telix has provided Grupo GSH with an exclusive license to manufacture, distribute and market Illuccix® in Brazil[2]. The marketing authorization is granted to Telix's partner R2PHARMA,Brazil'sleading cold kit manufacturer, nuclear pharmacy and cyclotron network, and a subsidiary of GSH...
PR Newswire
18/03/2025

TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on…

TAIPEI, March 17, 2025 /PRNewswire/ -- TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study evaluating TMB-365/TMB-380 long-acting dual bNAb regimen for HIV maintenance therapy. This regimen, which is the first of its kind, offers a viable alternative to daily oral cART for individuals living with HIV. TAIPEI , March 17, 2025 /PRNewswire/ --TaiMed Biologics (4147 TWO), an innovation-driven biotech company, has Phase 2a clinical study...
PR Newswire
17/03/2025

Oncology Market Assessment: Strategic Insights for Investment or Divestment |…

With a proven track record in pharma market assessment, DelveInsight specializes in asset prioritization and checkpoint inhibitor CPI evaluation. Our expertise in immune checkpoint inhibitor products, competitive intelligence, and market forecasting enables pharmaceutical companies to make data-driven investment decisions. By assessing the market landscape, unmet needs, and emerging checkpoint inhibitors, we provide strategic insights that shape asset development and commercialization…
PR Newswire
17/03/2025

VITRAKVI Maintains Market Leadership Across the 7MM Amid Growing TRK Inhibitor…

Bayer's VITRAKVI (larotrectinib) Overview Bayer's VITRAKVI (larotrectinib) Overview VITRAKVI is a targeted cancer therapy designed to treat solid tumors that harbor NTRK gene fusions. It functions as an inhibitor of TRK proteins (TRKA, TRKB, and TRKC). In enzyme assays, larotrectinib demonstrated potent inhibition of TRKA, TRKB, and TRKC, with IC50 values ranging from 5 to 11 nM, while another kinase, TNK2, required concentrations nearly 100 times higher for inhibition. The TRK proteins...
PR Newswire
17/03/2025

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing…

Conference call and webcast scheduled for March 18, 2025, at 8:30 A.M. EDT / 1:30 P.M. CET PARIS and CAMBRIDGE, Mass., March17, 2025(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext: NANO –– NASDAQ: NBTX – the '' Company ''), a late-stage clinical biotechnology company pioneering disruptive nanotherapeutic approaches to revolutionize treatment outcomes for millions of patients, today announced the execution of another disciplined step in its financial strategy through the amendment of the...
Nasdaq GlobeNewswire
17/03/2025

BioArctic receives Orphan Drug Designation for exidavnemab the US

Exidavnemab is being developed as a novel disease-modifying treatment for synucleinopathies such as MSA and Parkinson's disease. It is a monoclonal antibody (mAb) that selectively targets soluble alpha-synuclein aggregates, such as oligomers or protofibrils. By promoting the clearance of aggregated alpha-synuclein, exidavnemab may reduce the spreading and the negative effects of alpha-synuclein. Thereby, neuronal function and survival may be preserved, and disease progression ultimately slowed…
PR Newswire
17/03/2025

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging…

Media ReleaseCOPENHAGEN, Denmark; March 17, 2025 Results from Phase 2 RAINFOL TM -01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m 2led to a confirmed objective response rate (ORR) of 55.6% and median duration of response (mDOR) was not reached Phase 2 RAINFOL TM -01 and Phase 3 RAINFOL TM -02 trials evaluating the safety and efficacy of Rina-S at 120 mg/m 2 in patients with platinum resistant ovarian cancer...
Nasdaq GlobeNewswire
17/03/2025

Micro Bioreactor System Market Booms at 10.7% CAGR - Innovations in Pharma &…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-31S8869/Global_Micro_Bioreactor_System_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-31S8869/Global_Micro_Bioreactor_System_Market Major Factors Driving the Growth of Micro Bioreactor System Market: The Micro Bioreactor System Market continues to evolve as stakeholders prioritize rapid, scalable, and cost-efficient methods for cultivating cells and producing...
PR Newswire
17/03/2025

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities…

ORION CORPORATIONSTOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 17 MARCH 2025 at 17.15 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly and indirectly by BlackRock, Inc. and its funds decreased on 14 March 2025 below five (5) per...
Nasdaq GlobeNewswire
17/03/2025

Clario announces acquisition of imaging provider NeuroRx

"We're excited to welcome NeuroRx to Clario," said Clario's chief executive officer, Chris Fikry, M.D. "This strategic acquisition reinforces our strong leadership in imaging and further expands our capabilities in neuroscience—an area of immense importance in advancing medical innovation. By augmenting our expertise in this critical therapeutic area, we are even better positioned to support our customers in developing life-changing drugs." "We're excited to welcome…
PR Newswire
17/03/2025
Altri  Comunicati